Research Topics
| Susan E KrownSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium studySusan E Krown
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Acquir Immune Defic Syndr 59:447-54. 2012....- Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunitiesSusan E Krown
AIDS Malignancy Consortium, c o The EMMES Corporation, Rockville, Maryland, USA
Curr Opin Oncol 23:463-8. 2011.... 
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcomaSusan E Krown
Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Infect Dis 203:1082-6. 2011..Although valganciclovir was not active against KS in this setting, other appropriately targeted anti-herpesviral strategies may prove to be more effective...- AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa?Susan E Krown
Melanoma Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cytokine Growth Factor Rev 18:395-402. 2007.... 
Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trialSusan E Krown
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Acquir Immune Defic Syndr 41:149-53. 2006..This study establishes a safe dose of IFN that can be used with HAART and, potentially, with other inhibitors of KS in future clinical trials...- Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcomaS E Krown
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Interferon Cytokine Res 18:209-14. 1998.... - Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanismsSusan E Krown
Clinical Immunology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Hematol Oncol Clin North Am 17:763-83. 2003.... - Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group studySusan E Krown
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Interferon Cytokine Res 22:295-303. 2002..These findings justify the use of lower, well-tolerated IFN doses for treatment of KS with currently used antiretroviral regimens... - Management of Kaposi sarcoma: the role of interferon and thalidomideS E Krown
Clinical Immunology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Curr Opin Oncol 13:374-81. 2001..Studies are ongoing to explore the optimal way to use these agents and their mechanisms of action... - Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanomaWen Jen Hwu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 106:2445-51. 2006..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated... - Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II studyWen Jen Hwu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 103:2590-7. 2005..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases... - Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanomaMiguel Angel Perales
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 16:2022-9. 2008..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant... - A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 gangliosidePaul B Chapman
Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Vaccine 22:2904-9. 2004..5 mg dose used in previous BEC2 trials. Prolonged booster immunizations did not induce or maintain antibody responses... - Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanomaWen Jen Hwu
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 21:3351-6. 2003..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases... - Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapyMary Cianfrocca
Department of Medicine, Northwestern University, Chicago, Illinois 60611, USA
Cancer 116:3969-77. 2010..A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined... - Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)Susan E Krown
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer 107:1883-90. 2006..These observations provide little support for the use of this combination for melanoma brain metastases unless safe and effective methods to prevent thrombosis are developed... - Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implicationsY B Su
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 22:610-6. 2004..CONCLUSION: TMZ at this dose and schedule results in CD4(+) lymphopenia in a majority of patients that can result in OIs. Pneumocystis pneumonia prophylaxis should be considered for patients who develop sustained lymphopenia on TMZ... - Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy ConsortiumBrett T Brinker
Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
Cancer 112:1083-8. 2008.... - Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanomaJianda Yuan
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY, USA
Cancer Immun 9:5. 2009..One patient had an increase in CD8+ IFN-gamma+ cells. This xenogeneic immunization strategy was safe and associated with minimal toxicity. There was also evidence of immune response... - Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21Govind Ragupathi
Laboratory of Tumor Vaccinology, Clinic Immunology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 9:5214-20. 2003..However, vaccination of patients with GD2-KLH has previously failed to induce a consistent relevant antibody response. We test here whether the use of GD2 lactone-KLH can overcome the low immunogenicity of GD2-KLH... - Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanomaJedd D Wolchok
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 15:2044-50. 2007..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells... - Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanomaJedd D Wolchok
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Melanoma Res 13:189-96. 2003..The observation of two partial responses has led to a phase II study to evaluate treatment with high dose paracetamol alone or in combination with BCNU... - Time for oncologists to opt in for routine opt-out HIV testing?Elizabeth Y Chiao
Department of Medicine, Baylor College of Medicine, and Health Services Research and Development, Department of Veterans Affairs Medical Center, Houston, Texas 77030, USA
JAMA 304:334-9. 2010..In addition, evidence is discussed for the potential of opt-out HIV testing to improve clinical outcomes by facilitating appropriate HIV management during cancer treatment for individuals who are found to be HIV positive... - Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot studyElizabeth A Stier
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Acquir Immune Defic Syndr 47:56-61. 2008..To evaluate prospectively the safety of the infrared coagulator (IRC) as a treatment for anal high-grade squamous intraepithelial lesions (HSILs) in HIV-infected individuals and to seek preliminary evidence for efficacy... - A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemicElizabeth Y Chiao
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Acquir Immune Defic Syndr 40:451-5. 2005..The incidence of SCCA has particularly increased among men and those between 30 and 54 years of age since the introduction of HAART... - Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcomaSusan E Krown
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Clin Oncol 22:399-402. 2004 - Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanomaDavid B Solit
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 14:8302-7. 2008..We conducted a phase II trial using the hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in melanoma patients. The primary end points were clinical responses and whether treatment inhibited MAPK pathway activity... - Update on non-acquired immunodeficiency syndrome-defining malignanciesElizabeth Y Chiao
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Curr Opin Oncol 15:389-97. 2003..SUMMARY: As the epidemiology of non-AIDS-defining malignancies continues to evolve, it is unclear whether the appropriate treatments and outcomes for these or other malignancies are changed for HIV-infected patients treated with HAART... - Use of liposomal anthracyclines in Kaposi's sarcomaSusan E Krown
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 31:36-52. 2004..Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV... - Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trialWen Jen Hwu
Departments of Medicine, Epidemiology and Biostatistics, and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2610-5. 2002..To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma... - Defining adequate surgery for primary melanomaSusan E Krown
N Engl J Med 350:823-5. 2004 - Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical studyScott R Evans
Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
J Clin Oncol 20:3236-41. 2002.... - More on HIV-associated Kaposi's sarcomaSusan E Krown
N Engl J Med 358:535-6; author reply 536. 2008 - Editorial comment: reducing the risk of non-AIDS defining cancersSusan E Krown
AIDS Read 18:30. 2008 - Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirusDirk P Dittmer
Department of Microbiology and Immunology, Center for AIDS Research and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Curr Opin Oncol 19:452-7. 2007..To summarize major recent findings on the biology of human herpesvirus-8, i.e. Kaposi's sarcoma-associated herpesvirus, and the implications of these findings for Kaposi's sarcoma treatment... - Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium StudyBruce J Dezube
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Clin Oncol 24:1389-94. 2006..The aim of this trial was to extend these initial observations... - Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcomaSteven A Miles
AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, 2001 Third Avenue South, Room 1078, Birmingham, AL 35223, USA
AIDS 16:421-9. 2002..CONCLUSION: Oral 9-cis-retinoic acid is an active antitumor drug for AIDS-related Kaposi's sarcoma. Treatment is associated with skin and constitutional toxicity and further studies are needed to improve its long-term tolerance... - Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium studyMary Cianfrocca
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
J Clin Oncol 20:153-9. 2002..The most common adverse event was dose-related photosensitivity. Antitumor activity was noted. Further evaluation of COL-3 for the treatment of KS is warranted... - Breast cancer in the setting of HIV infection: cause for concern?Susan E Krown
Cancer Invest 20:590-2. 2002 - Editorial comment: adjuvant radiotherapy for testicular cancer--balancing cancer treatment with HIV managementSusan E Krown
AIDS Read 14:190. 2004
Research Grants
- AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUMSusan Krown; Fiscal Year: 2005..In sum, our scientific and clinical resources make us uniquely positioned to continue to contribute to the collaborative clinical trials effort that has been developed in the AMC over the past 3 years. ..